NorthWest Biotherapeutics Inc (NWBO)

[hyperopia]

george, the increased potency wasn’t part of the ASCO presentation, and no extrapolation is necessary; Northwest Bio announced it many years ago:

NW Bio Receives U.S. Patent On Broad Processes For Producing More Potent Dendritic Cells
Next Generation Technology Already In DCVax®-Direct; Will Be Applicable To All DCVax® Products

BETHESDA, Md., March 18, 2013 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that it has been issued a key U.S. patent (#8389278) covering novel processes for manufacturing human dendritic cells.  The cells produced through these processes are much more potent in their capacity to activate the immune system than those produced by the standard methods used throughout academia and industry today to produce dendritic cells. . . .

Building upon the pure immature dendritic cells, NW Bio's patented methods develop mature and activated dendritic cells that are far more potent than dendritic cells produced in the standard way.  For example, NW Bio's dendritic cells produce as much as 10X or more the amount of signaling compounds which are key to mobilizing other active agents of the immune system, such as T cells (which infiltrate and attack tumors) and B cells (which produce antibodies).

NW Bio is already using these next generation methods for producing more potent dendritic cells in its production of DCVax-Direct.  The same patented methods for activating dendritic cells were also used in the pre-clinical animal studies with DCVax-Direct.  In those studies, injection of these potent dendritic cells into some of the tumors in each of the animals resulted in complete clearance of all tumors (both the tumors injected with DCVax-Direct and the tumors not injected) in 80-100% of the animals in the various studies, indicating a system-wide immune response. . .

https://www.prnewswire.com/news-releases/nw-bio-receives-us-patent-on-broad-processes-for-producing-more-potent-dendritic-cells-198760831.html

This knowledge of increased potency and cytokine secretion, which correlates with increased survival, was gained during studies with DCVax-Direct using various maturation/activation agents, including poly I:C. Coincidentally, around that same time, UCLA began a trial to determine which adjuvant, a TLR-7 agonist, Resiquimod (R-848), or a TLR-3 agonist, Hiltonol (poly ICLC) combined with DCVax-L, increased survival more. As you may know, the combination with poly ICLC, produced superior survival results. (54 months with Hiltonol vs 28 months with Resiquimod, and 20 months with placebo)

The point of those “further thoughts” in that previous post was, that despite the fact that historically impressive clinical trial results were finally published last year, and Northwest Bio (Dr. Bosch) disclosed some critical additional information about the effectiveness of DCVax at ASCO, Northwest Bio actually knows far more, (and has a lot more intellectual property) than has recently been discussed. Patents for other innovations have been layered in with that broad patent since that announcement a decade ago. For example, last year, flipper brought to this boards attention, a patent for methods to produce “hyperactivated dendritic cells.” All of Northwest Bio’s intellectual property creates a high bar for others to overcome, as well as a lot of value to be unlocked in the future.